Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.

Wright TD, Raybuck C, Bhatt A, Monlish D, Chakrabarty S, Wendekier K, Gartland N, Gupta M, Burow ME, Flaherty PT, Cavanaugh JE.

J Cell Biochem. 2019 Aug 28. doi: 10.1002/jcb.29350. [Epub ahead of print]

PMID:
31464004
2.

Novel Diphenylamine Analogs Induce Mesenchymal to Epithelial Transition in Triple Negative Breast Cancer.

Bhatt AB, Gupta M, Hoang VT, Chakrabarty S, Wright TD, Elliot S, Chopra IK, Monlish D, Anna K, Burow ME, Cavanaugh JE, Flaherty PT.

Front Oncol. 2019 Jul 30;9:672. doi: 10.3389/fonc.2019.00672. eCollection 2019.

3.

Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs.

Hasan M, Marzouk MA, Adhikari S, Wright TD, Miller BP, Matossian MD, Elliott S, Wright M, Alzoubi M, Collins-Burow BM, Burow ME, Holzgrabe U, Zlotos DP, Stratford RE, Witt-Enderby PA.

Mol Pharmacol. 2019 Aug;96(2):272-296. doi: 10.1124/mol.119.116202. Epub 2019 Jun 20.

PMID:
31221824
4.

Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models.

Sabol RA, Bowles AC, Côté A, Wise R, O'Donnell B, Matossian MD, Hossain FM, Burks HE, Del Valle L, Miele L, Collins-Burow BM, Burow ME, Bunnell BA.

Breast Cancer Res. 2019 May 22;21(1):67. doi: 10.1186/s13058-019-1153-9.

5.

Obesity-Altered Adipose Stem Cells Promote ER⁺ Breast Cancer Metastasis through Estrogen Independent Pathways.

Sabol RA, Beighley A, Giacomelli P, Wise RM, Harrison MAA, O'Donnnell BA, Sullivan BN, Lampenfeld JD, Matossian MD, Bratton MR, Wang G, Collins-Burow BM, Burow ME, Bunnell BA.

Int J Mol Sci. 2019 Mar 20;20(6). pii: E1419. doi: 10.3390/ijms20061419.

6.

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model.

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, Martin EC, Collins-Burow BM, Burow ME.

BMC Cancer. 2019 Mar 7;19(1):205. doi: 10.1186/s12885-019-5401-2.

7.

Loss of Forkhead Box O3 Facilitates Inflammatory Colon Cancer: Transcriptome Profiling of the Immune Landscape and Novel Targets.

Penrose HM, Cable C, Heller S, Ungerleider N, Nakhoul H, Baddoo M, Hartono AB, Lee SB, Burow ME, Flemington EF, Crawford SE, Savkovic SD.

Cell Mol Gastroenterol Hepatol. 2019;7(2):391-408. doi: 10.1016/j.jcmgh.2018.10.003. Epub 2018 Oct 13.

8.

Engineering Breast Cancer Microenvironments and 3D Bioprinting.

Belgodere JA, King CT, Bursavich JB, Burow ME, Martin EC, Jung JP.

Front Bioeng Biotechnol. 2018 May 24;6:66. doi: 10.3389/fbioe.2018.00066. eCollection 2018. Review.

9.

Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model.

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Bunnell BA, Martin EC, Burow ME, Collins-Burow BM.

Oncoscience. 2018 Apr 29;5(3-4):99-108. doi: 10.18632/oncoscience.412. eCollection 2018 Mar.

10.

Structure activity relationships of anthranilic acid-based compounds on cellular and in vivo mitogen activated protein kinase-5 signaling pathways.

Chakrabarty S, Monlish DA, Gupta M, Wright TD, Hoang VT, Fedak M, Chopra I, Flaherty PT, Madura J, Mannepelli S, Burow ME, Cavanaugh JE.

Bioorg Med Chem Lett. 2018 Jul 15;28(13):2294-2301. doi: 10.1016/j.bmcl.2018.05.029. Epub 2018 May 20. No abstract available.

PMID:
29803729
11.

ZB716, a steroidal selective estrogen receptor degrader (SERD), is orally efficacious in blocking tumor growth in mouse xenograft models.

Guo S, Zhang C, Bratton M, Mottamal M, Liu J, Ma P, Zheng S, Zhong Q, Yang L, Wiese TE, Wu Y, Ellis MJ, Matossian M, Burow ME, Miele L, Houtman R, Wang G.

Oncotarget. 2018 Jan 8;9(6):6924-6937. doi: 10.18632/oncotarget.24023. eCollection 2018 Jan 23.

12.

Mirna biogenesis pathway is differentially regulated during adipose derived stromal/stem cell differentiation.

Martin EC, Qureshi AT, Llamas CB, Burow ME, King AG, Lee OC, Dasa V, Freitas MA, Forsberg JA, Elster EA, Davis TA, Gimble JM.

Adipocyte. 2018;7(2):96-105. doi: 10.1080/21623945.2018.1423911. Epub 2018 Feb 7.

13.

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer.

Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O'Donnell B, Miller KS, Wahba BM, Bunnell BA, Moroz K, Zea AH, Jones SD, Ochoa AC, Al-Khami AA, Hossain F, Riker AI, Rhodes LV, Martin EC, Miele L, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2018 Jun;169(2):381-390. doi: 10.1007/s10549-018-4685-2. Epub 2018 Feb 1.

14.

Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.

Zhou W, Guo S, Liu M, Burow ME, Wang G.

Curr Med Chem. 2019;26(17):3026-3041. doi: 10.2174/0929867324666170830111531. Review.

15.

Novel application of the published kinase inhibitor set to identify therapeutic targets and pathways in triple negative breast cancer subtypes.

Matossian MD, Elliott S, Hoang VT, Burks HE, Phamduy TB, Chrisey DB, Zuercher WJ, Drewry DH, Wells C, Collins-Burow B, Burow ME.

PLoS One. 2017 Aug 3;12(8):e0177802. doi: 10.1371/journal.pone.0177802. eCollection 2017.

16.

Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.

Anbalagan M, Sheng M, Fleischer B, Zhang Y, Gao Y, Hoang V, Matossian M, Burks HE, Burow ME, Collins-Burow BM, Hangauer D, Rowan BG.

Mol Cancer Res. 2017 Nov;15(11):1491-1502. doi: 10.1158/1541-7786.MCR-16-0297-T. Epub 2017 Jul 27.

17.

Glycinol enhances osteogenic differentiation and attenuates the effects of age on mesenchymal stem cells.

Strong AL, Jones RB Jr, Glowacki J, Boue SM, Burow ME, Bunnell BA.

Regen Med. 2017 Jul;12(5):513-524. doi: 10.2217/rme-2016-0148. Epub 2017 Jul 18.

PMID:
28718749
18.

Laser direct-write based fabrication of a spatially-defined, biomimetic construct as a potential model for breast cancer cell invasion into adipose tissue.

Vinson BT, Phamduy TB, Shipman J, Riggs B, Strong AL, Sklare SC, Murfee WL, Burow ME, Bunnell BA, Huang Y, Chrisey DB.

Biofabrication. 2017 May 11;9(2):025013. doi: 10.1088/1758-5090/aa6bad.

PMID:
28382922
19.

Osteoinductive effects of glyceollins on adult mesenchymal stromal/stem cells from adipose tissue and bone marrow.

Bateman ME, Strong AL, Hunter RS, Bratton MR, Komati R, Sridhar J, Riley KE, Wang G, Hayes DJ, Boue SM, Burow ME, Bunnell BA.

Phytomedicine. 2017 Apr 15;27:39-51. doi: 10.1016/j.phymed.2017.02.003. Epub 2017 Feb 14.

PMID:
28314478
20.

Oncogenic signaling of MEK5-ERK5.

Hoang VT, Yan TJ, Cavanaugh JE, Flaherty PT, Beckman BS, Burow ME.

Cancer Lett. 2017 Apr 28;392:51-59. doi: 10.1016/j.canlet.2017.01.034. Epub 2017 Jan 30. Review.

21.

The Effects of Endocrine Disruptors on Adipogenesis and Osteogenesis in Mesenchymal Stem Cells: A Review.

Bateman ME, Strong AL, McLachlan JA, Burow ME, Bunnell BA.

Front Endocrinol (Lausanne). 2017 Jan 9;7:171. doi: 10.3389/fendo.2016.00171. eCollection 2016. Review.

22.

Obesity Enhances the Conversion of Adipose-Derived Stromal/Stem Cells into Carcinoma-Associated Fibroblast Leading to Cancer Cell Proliferation and Progression to an Invasive Phenotype.

Strong AL, Pei DT, Hurst CG, Gimble JM, Burow ME, Bunnell BA.

Stem Cells Int. 2017;2017:9216502. doi: 10.1155/2017/9216502. Epub 2017 Dec 17.

23.

MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.

Martin EC, Conger AK, Yan TJ, Hoang VT, Miller DF, Buechlein A, Rusch DB, Nephew KP, Collins-Burow BM, Burow ME.

FEBS Lett. 2017 Jan;591(2):382-392. doi: 10.1002/1873-3468.12538. Epub 2017 Jan 12.

24.

Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation.

Conger AK, Martin EC, Yan TJ, Rhodes LV, Hoang VT, La J, Anbalagan M, Burks HE, Rowan BG, Nephew KP, Collins-Burow BM, Burow ME.

Noncoding RNA. 2016 Sep 21;2(3). pii: E8. doi: 10.3390/ncrna2030008.

25.

Induction of HOXA9 expression in three-dimensional organotypic culture of the Claudin-low breast cancer cells.

Li M, Li X, Zhuang Y, Wang Y, Burow ME, Collins-Burow B, Xue M, Song C, Shan B.

Oncotarget. 2016 Aug 9;7(32):51503-51514. doi: 10.18632/oncotarget.10491.

26.

Laser Direct-Write Onto Live Tissues: A Novel Model for Studying Cancer Cell Migration.

Burks HE, Phamduy TB, Azimi MS, Saksena J, Burow ME, Collins-Burow BM, Chrisey DB, Murfee WL.

J Cell Physiol. 2016 Nov;231(11):2333-8. doi: 10.1002/jcp.25363. Epub 2016 Mar 15.

27.

Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1.

Carriere PP, Llopis SD, Naiki AC, Nguyen G, Phan T, Nguyen MM, Preyan LC, Yearby L, Pratt J, Burks H, Davenport IR, Nguyen TA, Parker-Lemieux K, Payton-Stewart F, Williams CC, Boué SM, Burow ME, Collins-Burow B, Hilliard A, Davidson AM, Tilghman SL.

Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010010. doi: 10.3390/ijerph13010010.

28.

Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1.

Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM.

Oncogenesis. 2015 Oct 5;4:e168. doi: 10.1038/oncsis.2015.27.

29.

Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers.

Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, Llamas C, Bowles AC, Dutreil MF, Zhang S, Gimble JM, Burow ME, Bunnell BA.

Breast Cancer Res. 2015 Aug 19;17:112. doi: 10.1186/s13058-015-0622-z.

30.

Printing cancer cells into intact microvascular networks: a model for investigating cancer cell dynamics during angiogenesis.

Phamduy TB, Sweat RS, Azimi MS, Burow ME, Murfee WL, Chrisey DB.

Integr Biol (Camb). 2015 Sep;7(9):1068-78. doi: 10.1039/c5ib00151j. Epub 2015 Jul 20.

31.

Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.

Rhodes LV, Martin EC, Segar HC, Miller DF, Buechlein A, Rusch DB, Nephew KP, Burow ME, Collins-Burow BM.

Oncotarget. 2015 Jun 30;6(18):16638-52.

32.

Soy glyceollins regulate transcript abundance in the female mouse brain.

Bamji SF, Page RB, Patel D, Sanders A, Alvarez AR, Gambrell C, Naik K, Raghavan AM, Burow ME, Boue SM, Klinge CM, Ivanova M, Corbitt C.

Funct Integr Genomics. 2015 Sep;15(5):549-61. doi: 10.1007/s10142-015-0442-3. Epub 2015 May 8.

33.

Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer.

Bratton MR, Martin EC, Elliott S, Rhodes LV, Collins-Burow BM, McLachlan JA, Wiese TE, Boue SM, Burow ME.

J Steroid Biochem Mol Biol. 2015 Jun;150:17-23. doi: 10.1016/j.jsbmb.2014.12.014. Epub 2015 Mar 12.

34.

Stranded Whole Transcriptome RNA-Seq for All RNA Types.

Miller DF, Yan PX, Fang F, Buechlein A, Ford JB, Tang H, Huang TH, Burow ME, Liu Y, Rusch DB, Nephew KP.

Curr Protoc Hum Genet. 2015 Jan 20;84:11.14.1-23. doi: 10.1002/0471142905.hg1114s84.

35.

miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling.

Martin EC, Krebs AE, Burks HE, Elliott S, Baddoo M, Collins-Burow BM, Flemington EK, Burow ME.

Genes Cancer. 2014 Sep;5(9-10):353-64.

36.

Elevated expression of long intergenic non-coding RNA HOTAIR in a basal-like variant of MCF-7 breast cancer cells.

Zhuang Y, Nguyen HT, Burow ME, Zhuo Y, El-Dahr SS, Yao X, Cao S, Flemington EK, Nephew KP, Fang F, Collins-Burow B, Rhodes LV, Yu Q, Jayawickramarajah J, Shan B.

Mol Carcinog. 2015 Dec;54(12):1656-67. doi: 10.1002/mc.22237. Epub 2014 Oct 18.

37.

microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.

Martin EC, Rhodes LV, Elliott S, Krebs AE, Nephew KP, Flemington EK, Collins-Burow BM, Burow ME.

Mol Cancer. 2014 Oct 6;13:229. doi: 10.1186/1476-4598-13-229.

38.

Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells.

Strong AL, Burow ME, Gimble JM, Bunnell BA.

Stem Cells. 2015 Feb;33(2):318-26. doi: 10.1002/stem.1857. Review.

39.

Novel daidzein analogs enhance osteogenic activity of bone marrow-derived mesenchymal stem cells and adipose-derived stromal/stem cells through estrogen receptor dependent and independent mechanisms.

Strong AL, Ohlstein JF, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Gimble JM, Burow ME, Wang G, Bunnell BA.

Stem Cell Res Ther. 2014 Aug 28;5(4):105. doi: 10.1186/scrt493.

40.

Bisphenol A enhances adipogenic differentiation of human adipose stromal/stem cells.

Ohlstein JF, Strong AL, McLachlan JA, Gimble JM, Burow ME, Bunnell BA.

J Mol Endocrinol. 2014 Dec;53(3):345-53. doi: 10.1530/JME-14-0052. Epub 2014 Aug 20.

41.

Effects of the endocrine-disrupting chemical DDT on self-renewal and differentiation of human mesenchymal stem cells.

Strong AL, Shi Z, Strong MJ, Miller DF, Rusch DB, Buechlein AM, Flemington EK, McLachlan JA, Nephew KP, Burow ME, Bunnell BA.

Environ Health Perspect. 2015 Jan;123(1):42-8. doi: 10.1289/ehp.1408188. Epub 2014 Jul 11.

42.

Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.

Gestaut MM, Antoon JW, Burow ME, Beckman BS.

Pharmacol Rep. 2014 Feb;66(1):174-8. doi: 10.1016/j.pharep.2013.08.014. Epub 2014 Feb 3.

PMID:
24905325
43.

Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.

Strong AL, Jiang Q, Zhang Q, Zheng S, Boue SM, Elliott S, Burow ME, Bunnell BA, Wang G.

ACS Med Chem Lett. 2013 Dec 10;5(2):143-8. doi: 10.1021/ml400397k. eCollection 2014 Feb 13.

44.

Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.

Rhodes LV, Tate CR, Segar HC, Burks HE, Phamduy TB, Hoang V, Elliott S, Gilliam D, Pounder FN, Anbalagan M, Chrisey DB, Rowan BG, Burow ME, Collins-Burow BM.

Breast Cancer Res Treat. 2014 Jun;145(3):593-604. doi: 10.1007/s10549-014-2979-6. Epub 2014 May 9.

45.

Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways.

Strong AL, Strong TA, Rhodes LV, Semon JA, Zhang X, Shi Z, Zhang S, Gimble JM, Burow ME, Bunnell BA.

Breast Cancer Res. 2013;15(5):R102.

46.

MEK5/ERK5 signaling suppresses estrogen receptor expression and promotes hormone-independent tumorigenesis.

Antoon JW, Martin EC, Lai R, Salvo VA, Tang Y, Nitzchke AM, Elliott S, Nam SY, Xiong W, Rhodes LV, Collins-Burow B, David O, Wang G, Shan B, Beckman BS, Nephew KP, Burow ME.

PLoS One. 2013 Aug 9;8(8):e69291. doi: 10.1371/journal.pone.0069291. eCollection 2013.

47.

Postharvest accumulation of resveratrol and piceatannol in sugarcane with enhanced antioxidant activity.

Boue SM, Shih BY, Burow ME, Eggleston G, Lingle S, Pan YB, Daigle K, Bhatnagar D.

J Agric Food Chem. 2013 Sep 4;61(35):8412-9. doi: 10.1021/jf4020087. Epub 2013 Aug 23.

PMID:
23931742
48.

PDZ-RhoGEF is essential for CXCR4-driven breast tumor cell motility through spatial regulation of RhoA.

Struckhoff AP, Rana MK, Kher SS, Burow ME, Hagan JL, Del Valle L, Worthylake RA.

J Cell Sci. 2013 Oct 1;126(Pt 19):4514-26. doi: 10.1242/jcs.132381. Epub 2013 Jul 18.

49.

Differences in gastric carcinoma microenvironment stratify according to EBV infection intensity: implications for possible immune adjuvant therapy.

Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, Lacey MR, Strong AL, Lehman TA, Seddon MB, Lin Z, Concha M, Baddoo M, Ferris M, Swan KF, Sullivan DE, Burow ME, Taylor CM, Flemington EK.

PLoS Pathog. 2013;9(5):e1003341. doi: 10.1371/journal.ppat.1003341. Epub 2013 May 9.

50.

A new method for stranded whole transcriptome RNA-seq.

Miller DF, Yan PS, Buechlein A, Rodriguez BA, Yilmaz AS, Goel S, Lin H, Collins-Burow B, Rhodes LV, Braun C, Pradeep S, Rupaimoole R, Dalkilic M, Sood AK, Burow ME, Tang H, Huang TH, Liu Y, Rusch DB, Nephew KP.

Methods. 2013 Sep 15;63(2):126-34. doi: 10.1016/j.ymeth.2013.03.023. Epub 2013 Apr 1.

Supplemental Content

Loading ...
Support Center